Investing.com -- Deutsche Bank upgraded Gilead Sciences Inc (NASDAQ:GILD) to "Buy" from "Hold" and raised its price target to $120 from $80 on long-term revenue growth potential in the company’s core HIV treatment franchise.
The bank highlighted the upcoming 2025 launch of lenacapavir for pre-exposure prophylaxis (PrEP) as a key driver, forecasting $619 million in LEN sales for fiscal 2025 and $3.7 billion by 2035. The firm believes Gilead’s long-acting HIV treatments will help offset future patent expirations, sustaining revenue growth into the next decade.
Despite Gilead’s stock trading at a higher valuation than its historical average, Deutsche Bank (ETR:DBKGn) argues it remains attractive relative to biopharma peers with long-term growth prospects, such as Eli Lilly (NYSE:LLY) and Vertex Pharmaceuticals (NASDAQ:VRTX).
Shares of Gilead were trading up 2%.
Related Articles
Deutsche Bank upgrades Gilead on its HIV treatment franchise
Iraq-Kurdistan pipeline set to reopen
Salesforce: BofA says channel checks are positive
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.